Drug · CHEMBL499
TIMOLOL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. TIMOLOL. Drugs and targets, record CHEMBL499. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL499
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Open Targets' highest stage
- Approval, for 5 of its 26 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD
- Open Targets
Targets2
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| ADRB1 | Beta-1 adrenergic receptor | Beta-1 adrenergic receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/153 |
| ADRB2 | Beta-2 adrenergic receptor | Beta-2 adrenergic receptor antagonist | ANTAGONIST | https://conductscience.org/library/genes/154 |
Source ChEMBL
Diseases26
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
1 to 10 of 26Source Open Targets
See all 26 diseasesTrials176
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 4 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 9 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT01177098 | Safety and Efficacy of a New Formulation of Bimatoprost/Timolol Ophthalmic Solution Compared With Bimatoprost/Timolol Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension | Phase 3 | 561 | 2013-03-12 | timolol | Its name | ClinicalTrials.gov |
| NCT01342081 | DE-111 Against Tafluprost Ophthalmic Solution 0.0015% Alone and Concomitant Use of Tafluprost Ophthalmic Solution 0.0015% Plus Timolol Ophthalmic Solution 0.5% | Phase 3 | 489 | 2015-05-14 | timolol | Its name | ClinicalTrials.gov |
| NCT01357616 | Fixed Combination Brinzolamide 1%/Timolol 0.5% Versus Brinzolamide 1% + Timolol 0.5% in Open-Angle Glaucoma or Ocular Hypertension | Phase 3 | 328 | 2014-03-13 | timolol | Its name | ClinicalTrials.gov |
| NCT00383019 | A Study Comparing Xalacom And Xalatan In Patients With Primary Open Angle Glaucoma (POAG) Or Ocular Hypertension (OH). | Phase 3 | 300 | 2009-05-27 | xalacom | Open Targets' reading, confirmed by the trial's result groups | ClinicalTrials.gov |
| NCT02278614 | Efficacy and Safety Assessment of T2347 Versus Xalacom® in Ocular Hypertensive or Glaucomatous Patients | Phase 3 | 242 | 2017-01-23 | timolol | Its name | ClinicalTrials.gov |
| NCT01229462 | Safety and Efficacy of Brimonidine Tartrate/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension | 238 | 2012-09-14 | brimonidine tartrate/timolol fixed combination, timolol | Its name | ClinicalTrials.gov | |
| NCT01068964 | Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension | 235 | 2012-01-20 | timolol | Its name | ClinicalTrials.gov | |
| NCT04910100 | Nebivolol 0.5, 1.0, or Timolol 0.5 Suspension Compared to Timolol 0.5 Solution to Treat Glaucoma/Ocular Hypertension | Phase 2 | 226 | 2024-04-17 | timolol | Its name | ClinicalTrials.gov |
| NCT01241240 | Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension | Phase 3 | 192 | 2014-09-10 | timolol | Its name | ClinicalTrials.gov |
| NCT01217606 | Safety and Efficacy of Triple Combination Therapy in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension | Phase 3 | 185 | 2015-11-09 | timolol | Its name | ClinicalTrials.gov |
1 to 10 of 176
See all 176 trialsComparisons in its trials50
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Bimatoprost/Timolol Formulation A vs Bimatoprost/Timolol Fixed Combination Ophthalmic Solution: serious adverse events | 4 of 278 | 4 of 282 | 560 | NCT01177098 | Trial comparisons |
| AZARGA (Test Group) vs AZOPT + TIMOLOL (Control Group): serious adverse events | 1 of 165 | 0 of 162 | 327 | NCT01357616 | Trial comparisons |
| T2347 vs Xalacom: serious adverse events | 0 of 127 | 1 of 115 | 242 | NCT02278614 | Trial comparisons |
| Timolol vs Latanoprost: deaths from any cause | 0 of 119 | 0 of 121 | 240 | NCT01677507 | Trial comparisons |
| Timolol vs Latanoprost: serious adverse events | 0 of 119 | 0 of 121 | 240 | NCT01677507 | Trial comparisons |
| Combigan® vs Alphagan® and Timolol Concurrent: serious adverse events | 1 of 120 | 1 of 116 | 236 | NCT01229462 | Trial comparisons |
| 0.03% Bimatoprost/0.5% Timolol in Same Bottle vs 0.03% Bimatoprost and 0.5% Timolol in Separate Bottles: serious adverse events | 0 of 121 | 2 of 114 | 235 | NCT01068964 | Trial comparisons |
| AZARGA vs COSOPT: serious adverse events | 0 of 112 | 0 of 112 | 224 | NCT01340014 | Trial comparisons |
| Triple Combination Therapy vs Combigan®: serious adverse events | 3 of 93 | 0 of 98 | 191 | NCT01241240 | Trial comparisons |
| Triple Combination Therapy vs Combigan®: serious adverse events | 1 of 90 | 1 of 95 | 185 | NCT01217606 | Trial comparisons |
1 to 10 of 50
See all 50 comparisons in its trialsPapers from its trials78
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL499
GET https://conductscience.org/api/drugs/v1/CHEMBL499/diseases?page=2